围术期特瑞普利单抗治疗III期可切除非小细胞肺癌的手术结局:Neotorch随机临床试验事后分析
该多中心双盲安慰剂对照3期试验纳入404例可切除IIIA/IIIB期NSCLC患者,314例接受手术。特瑞普利单抗组肿瘤及淋巴结降期率均显著更高,且降期与更优EFS相关。
要点
- 特瑞普利单抗联合化疗可显著降低可切除III期NSCLC的手术取消率。
- 两组手术并发症相似,未观察到新的安全信号。
- 特瑞普利单抗组肿瘤和淋巴结降期率更高,且降期与更优EFS相关。
核心结论
- 围术期特瑞普利单抗联合化疗与单纯化疗相比围术期结局相当,无新安全信号,并可通过有效肿瘤降期改善可切除III期NSCLC患者生存。
研究设计与样本
- 多中心、双盲、安慰剂对照3期随机临床试验(Neotorch),中国50个中心,纳入404例可切除IIIA或IIIB期NSCLC患者。
- 患者1:1随机接受特瑞普利单抗(240 mg)联合铂类化疗或安慰剂联合铂类化疗,术前3周期、术后1周期,随后特瑞普利单抗或安慰剂单药维持13周期。
- 本事后分析纳入314例接受手术的患者(特瑞普利单抗组166例,安慰剂组148例;中位年龄60岁,男性90%,女性10%)。
主要发现
- 特瑞普利单抗组微创手术、R0切除和肺叶切除比例略高于安慰剂组,两组手术并发症相似。
临床怎么用
- 对于可切除III期NSCLC,围术期特瑞普利单抗联合化疗未增加手术并发症,可考虑用于新辅助治疗以促进降期并降低手术取消风险。
- 术后肿瘤和淋巴结降期情况可用于评估EFS获益,指导术后随访和辅助治疗决策。
局限性
- 本分析为事后分析,手术结局并非主要终点。
- 中位随访时间较短(18.3个月),EFS数据尚不成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Perioperative immunotherapy has improved clinical outcomes for patients with early-stage non-small cell lung cancer (NSCLC). The influence of immune checkpoint inhibitor in combination with chemotherapy on surgical outcomes remains to be explored. OBJECTIVE: To evaluate perioperative toripalimab in combination with chemotherapy on surgical outcomes. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind, placebo-controlled phase 3 randomized clinical trial (Neotorch study) enrolled patients with resectable stage III NSCLC and took place at 50 centers in China. Patients who had histologically confirmed resectable stage IIIA or IIIB NSCLC were eligible. These data were analyzed from July 2024 to March 2026. INTERVENTIONS: Patients were randomized (1:1) to receive toripalimab (240 mg) plus platinum-based chemotherapy or placebo plus platinum-based chemotherapy for 3 cycles before surgery and 1 cycle after surgery, followed by maintenance with toripalimab or placebo alone for 13 cycles. MAIN OUTCOMES AND MEASURES: Surgical outcomes, including perioperative complications, tumor downstaging, and lymph node downstaging, and their association with event-free survival (EFS), were studied in this post hoc analysis. RESULTS: Among 404 patients enrolled, 314 patients (median [SD] age 60 [6.82] years; 90% of patients were male and 10% were female) underwent surgery (166 in toripalimab group and 148 in placebo group). Percentage of patients canceling surgery (17.8% vs 26.7%; P = .03) was significantly lower in the toripalimab group. Proportions of minimally invasive surgery, R0 resection, and lobectomy were slightly higher in the toripalimab group. Surgical complications were similar between the 2 groups. Rates of postsurgery tumor (80.7% vs 50.7%; P < .001) and lymph node downstaging (67.5% vs 48.6%; P = .001) were both significantly higher with toripalimab than placebo. With a median follow-up of 18.3 months, a better EFS was noticed in the toripalimab group. Tumor and lymph node downstaging in the toripalimab group were both associated with better EFS than nondownstaging (median EFS, not estimable [NE] vs 17.5 months; P = .004 and NE vs 19.2 months; P = .001, respectively), and were also associated with even better EFS than tumor and lymph node downstaging in the placebo group (median EFS, NE vs 22.0 months; P = .002 and NE vs NE; P = .009, respectively). CONCLUSIONS AND RELEVANCE: In this study, perioperative toripalimab plus chemotherapy showed comparable perioperative outcomes, as with chemotherapy alone without new safety signals, and could help improve survival through effective tumor downstaging in patients with resectable stage III NSCLC. TRIAL REGISTRATION: ClinicalTrials. gov Identifier: NCT04158440.
引用
- Fang W, Wang Y, Wang W, et al. Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical Trial. JAMA Surg. 2026. PMID: 42455561. doi:10.1001/jamasurg.2026.2711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。